BioStock: BioInvent kicks off 2025 with positive clinical data

With multiple data readouts expected from its four clinical programs, BioInvent has started 2025 on a high note. The year’s first clinical data show encouraging initial efficacy in the triple-combination of BI-1206, rituximab, and Calquence for treating non-Hodgkin’s lymphoma. The company has also reported promising findings for BI-1910 as single agent in the phase I study targeting solid tumors. BioStock reached out to Martin Welschof, CEO of BioInvent for a comment.

Read the full interview with Martin Welschof at biostock.se:

https://www.biostock.se/en/2025/01/bioinvent-kicks-off-2025-with-positive-clinical-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/